Pricing, Policy and Regulation
Today's issue
Refine Search
Latest Pricing, Policy and Regulation News & Features
Biotechnology
Johnson & Johnson (NYSE: JNJ) has received a new European approval for a combination of Rybrevant (amivantamab) plus chemotherapy in lung cancer. 28 June 2024
Pharmaceutical
Latin American countries have taken on the task of exploring how a tool such as regulatory reliance can be better used to improve health ecosystems in the region, based on trust and teamwork, without having to complete their own thorough reviews that demand time and resources. 28 June 2024
Pharmaceutical
Shares in Verona Pharma closed nearly 7% higher on Wednesday. 27 June 2024
Pharmaceutical
The US Department of Health and Human Services (HHS)—through the Centers for Medicare and Medicaid Services (CMS)—has announced that some Medicare enrollees will pay less for 64 drugs available through Medicare Part B. 27 June 2024
Biotechnology
It was a milestone achievement when Moderna last month announced its first US Food and Drug Administration (FDA) approval outside COVID-19. 27 June 2024
Biotechnology
The UK’s health technology assessor has changed its tune regarding CSL Behring’s Hemgenix (etranacogene dezaparvovec), recommending the product for use in England and Wales. 27 June 2024
Pharmaceutical
Danish drugmaker Novo Nordisk’s GLP-1 receptor agonist Wegovy (semaglutide) has been approved in China for long-term weight management. 26 June 2024
Pharmaceutical
London-based pharma major GSK—one of the UK’s flagship companies—has suffered a galling defeat on home soil to US rival Pfizer. 25 June 2024
Pharmaceutical
Russia will speed up the process of launching generics of original drugs that have been withdrawn from the market by their producers in a move to ensure better security of the country in its pharmaceutical sector, reports The Pharma Letter’s local correspondent. 25 June 2024
Biotechnology
Swiss pharma giant Roche has announced that the European Commission has granted marketing authorization for Ocrevus (ocrelizumab) subcutaneous (SC) to treat relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). 25 June 2024
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze